Experience of using fluorescence cystoscopy in the diagnosis of superficial bladder cancer

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Experience of using fluorescence cystoscopy in the diagnosis of superficial bladder cancer. The study involved 103 patients of both sexes (mean age 58,7 ± 6,3 years) who underwent photodynamic diagnosis (PDD) of bladder cancer. For this purpose 5 mg of photoditazine were injected into the bladder dissolved in 20 ml of saline. The exposure time of the drug in the bladder was from 60 to 90 minutes. Then sequentially performed cystoscopy in white and blue light. For fluorescence diagnosis the light flux with a wavelength of 402 nm was used, which corresponded to the maximum peak of photoditazine absorption. The use of PDD revealed bladder cancer in all 103 patients, while in 69 (67 %) patients were identified in a total of 125 plots mucosa, fluorescent in blue light and unaltered in white light. Histological examination of these sites of mucosa in 52 (41.6 %) cases the tumor (transitional cell carcinoma) was morphologically confirmed, in 14 (11.2 %) cases of dysplasia was detected, in 15 (12 %) - squamous metaplasia of the urothelium, in 31 (24.8 %) - inflammatory changes in the urothelium, in 13 (10.4 %) - leukoplakia of the bladder. Thus, the diagnostic sensitivity of the standard cystoscopy in white light was 62.3 %, and PDD with intravesical use of the drug photodithazine - 96.7 %.

Full Text

Restricted Access

About the authors

Margarita Nikolayevna Slesarevskaya

First St. Petersburg State I. P. Pavlov Medical University

Email: mns-1971@yandex.ru
candidate of medical science, senior research fellow, Urology Department

Arkadiy Viktorovich Sokolov

First St. Petersburg State I. P. Pavlov Medical University

Email: soloo3@yandex.ru
head of Laser Medicine Department, urologist

References

  1. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность) / Под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена, 2013. 289 с.
  2. Матвеев Б. П., Фигурин К. М., Карякин О. Б. Рак мочевого пузыря. М., Вердана. 2001. 243 с.
  3. Lamm D. L. Long term resalts of intravesical therapy for superficial cancer (review) // Urol. Clin. North. Am. 1992. Vol. 19. P. 573-580
  4. Чиссов В. И., Соколов В. В., Булгакова Н. Н., Филоненко Е. В. Флюоресцентная эндоскопия, дермоскопия и спектрометрия в диагностике злокачественных опухолей различных локализаций // Российский биотерапевтический журнал. 2003. Т. 2, № 5. С. 45-56.
  5. Baert L., Berg R., Vamn Damme B. et al. Clinical fluorescence diagnosis of human bladder carcinoma following low-dose Photofrin injection // Urology. 1993. Vol. 41. P. 322-330.
  6. Nseyo U., DeHaven J., Dougherty T. et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: A long term experience // J. Clin. Laser. Med. Surg. 1998. Vol. 16. P. 61-68.
  7. Mauritio В., Laurence C., Karlheinz K. et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Та Т1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies // Eur. Urol. 2002. Vol. 41. P. 523-531.
  8. Kelly J. F., Snell M. E. Haemotoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder // J. Urol. 1976. Vol. 115, N 2. P.150-151.
  9. Benson Jr R. C., Farrow G., Kinsey J. et al. Detection and localization of in situ carcinoma of the bladder with haemotoporphyrin derivative // Mayo Clin. Proc. 1982. Vol. 57, N 9. P. 548-555.
  10. Datta S. N., Loh C. S., MacRobert A. J. et al. Quantitative studies of kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell carcinoma // Br. J. Cancer. 1998. Vol. 78. P. 1113-1118.

Statistics

Views

Abstract - 398

PDF (Russian) - 216

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2014 Slesarevskaya M.N., Sokolov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies